218 related articles for article (PubMed ID: 10867652)
41. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
42. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
43. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells.
Lee SY; Rhee YH; Jeong SJ; Lee HJ; Lee HJ; Jung MH; Kim SH; Lee EO; Ahn KS; Ahn KS; Kim SH
Environ Toxicol; 2011 Aug; 26(4):424-31. PubMed ID: 20196146
[TBL] [Abstract][Full Text] [Related]
44. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
45. Radioiodinated agents for imaging multidrug resistant tumors.
Kortylewicz ZP; Augustine AM; Nearman J; McGarry J; Baranowska-Kortylewicz J
Med Chem; 2009 Mar; 5(2):171-81. PubMed ID: 19275716
[TBL] [Abstract][Full Text] [Related]
46. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
47. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G
Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216
[TBL] [Abstract][Full Text] [Related]
48. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.
Lin ST; May EW; Chang JF; Hu RY; Wang LH; Chan HL
Cell Mol Life Sci; 2015 Jun; 72(12):2395-409. PubMed ID: 25596698
[TBL] [Abstract][Full Text] [Related]
49. Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
Takeshita H; Kusuzaki K; Murata H; Nakamura S; Ashihara T; Hirasawa Y
Anticancer Res; 1999; 19(6B):5235-8. PubMed ID: 10697541
[TBL] [Abstract][Full Text] [Related]
50. Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells.
Lin ST; Chou HC; Chang SJ; Chen YW; Lyu PC; Wang WC; Chang MD; Chan HL
J Proteomics; 2012 Oct; 75(18):5822-47. PubMed ID: 22889595
[TBL] [Abstract][Full Text] [Related]
51. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
52. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
Bidwell GL; Davis AN; Fokt I; Priebe W; Raucher D
Invest New Drugs; 2007 Aug; 25(4):313-26. PubMed ID: 17483874
[TBL] [Abstract][Full Text] [Related]
53. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
54. Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells.
Chu ES; Yow CM; Shi M; Ho RJ
Toxicol Lett; 2008 Sep; 181(1):7-12. PubMed ID: 18625294
[TBL] [Abstract][Full Text] [Related]
55. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
56. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
57. Restoration of intracellular drug accumulation in MDR cell line K562r does not mean reversal of its drug resistance.
Hu X; Chen WY
Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):422-6. PubMed ID: 7717067
[TBL] [Abstract][Full Text] [Related]
58. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
59. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
60. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
